The FDA is extending the Patient Engagement Advisory Committee for an additional two years — from Oct. 6, 2017 to Oct. 6, 2019.

The PEAC, which held its first meeting last month, considers a wide range of topics from patient preference in study design to patient-reported health outcomes, with the goal of integrating more patient perspectives into the FDA’s processes for regulating medical devices.

The committee also is tasked with providing recommendations on the safety and effectiveness of medical devices, as well as their regulation and use by patients.